Vivani Medical up on plans to begin first human study for obesity implant

Vivani Medical

11/07/2024 13:46

** Shares of biotech co Vivani Medical  VANI.O  rise 8.6% to
$1.35 premarket 
    ** Co expects to initiate its first human study to test its
obesity implant in Q4 in Australia, pending regulatory clearance
    ** The study will test its experimental GLP-1 implant for
chronic weight management in patients who are either obese or
overweight with a related comorbidity
    ** The study will be conducted to evaluate safety,
tolerability and how the body interacts with the implant for the
duration of the study 
    ** Data from the trial is projected to be available in 2025
- VANI 
    ** Up to last close, stock up 22.5% YTD 

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))